Skip to main content

Table 3 Characteristics associated with MDR-TB treatment outcomes

From: Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania

Clinical/microbiological characteristic Treatment success
N = 24
Treatment failure
N = 6
p-value
Mean age years ±SD 34 ± 10 28 ± 9 P = 0.20
Gender, Female (%N) 6 (25) 1 (16.7) P = 0.57
HIV infected (%N) 5 (20.8) 1 (20) P = 0.66
Smoking (%N) 6 (25) 0 P = 0.33
Prior treatment 21 (87.5) 4 (66.7) P = 0.25
Cavity on chest x-ray 6 (25) 2 (33.3) P = 0.65
PZA resistant (%N) by MGIT PZA 10 (41.6) 5 (83) P = 0.08
  1. SD standard deviation, HIV human immunodeficiency virus, PZA pyrazinamide